 "graph")
When US-based global health care major Abbott acquired the formulations business of Piramal Healthcare in a $3.7-billion deal in 2010, it had projected a revenue target of $2.5 billion within 10 years. As things stand today, this target seems an uphill task for the company to achieve.
The acquisition, a part of the multinational drugmaker’s strategy to expand its emerging market presence, propelled the pharma giant to No. 1 position in the domestic market. But recent government actions, including capping prices for drugs and stents, and curbs on sale of fixed-dose drug combinations (FDCs), have intensified the challenges for the
